Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Expert Opinion on Investigational DrugsOpen Access

Acute chest syndrome (ACS) in sickle cell disease (SCD): pathogenesis and pharmacotherapies in early clinical development

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSubarna ChakravortyAGAnne Greenough

Discussion

Loading...

Member takes

Overview

This review reveals the mechanisms of acute chest syndrome in sickle cell disease, highlighting pharmacotherapies in development.

Key Points

  • Acute chest syndrome is a critical complication of sickle cell disease, leading to high rates of ICU admissions and mortality in children.
  • Understanding of acute chest syndrome pathogenesis is advancing, driven by insights into inflammation and vascular obstruction.
  • The review discusses potential pharmacotherapies targeting various mechanisms involved in acute chest syndrome, including hydroxyurea use.
  • A multi-drug approach may be necessary to effectively treat acute chest syndrome, highlighting the complexity of this condition.

Cite This Study

Chakravorty et al. (2025) studied this question.

synapsesocial.com/papers/68c1d80554b1d3bfb60fa918https://doi.org/10.1080/13543784.2025.2551353
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HbS promotes TLR4-mediated monocyte activation and proinflammatory cytokine production in sickle cell disease2022 · 61 citations
  2. 2Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative2022 · 49 citations
  3. 3Respiratory management of acute chest syndrome in children with sickle cell disease2024 · 12 citations
  4. 4The modern use of hydroxyurea for children with sickle cell anemia2025 · 20 citations
  5. 5The Sickle-Cell Fiber Revisited2023 · 10 citations